Merger Rumors Shake Pharma Giants | Business and Finance News

Rumors of a $400 billion merger between AstraZeneca and Bristol Myers Squibb sent shockwaves through the market, triggering a 9% drop in AstraZeneca’s stock as investors balked at the risks — regulatory hurdles, patent expirations, and doubts about whether the combined cancer drug giant would be worth the chaos. While the deal could create an oncology powerhouse, skepticism runs deep: many believe AstraZeneca is better off growing organically, and Bristol Myers Squibb’s own struggles make this a risky bet. With speculation already causing volatility, shareholders may want to cash out while prices rise — and for now, both stocks look shaky without confirmation. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/5eab0da2832e19a5